<DOC>
	<DOCNO>NCT01480180</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial evaluate safety efficacy , include pharmacokinetics ( exposure trial drug body ) NNC 0129-0000-1003 ( N8-GP ) subject Haemophilia A .</brief_summary>
	<brief_title>Evaluation Safety Efficacy , Including Pharmacokinetics , NNC 0129-0000-1003 When Administered Treatment Prophylaxis Bleeding Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient severe congenital haemophilia A ( FVIII activity 1 % , accord medical record ) Documented history least 150 EDs ( exposure day ) FVIII product At least 12 year body weight least 35 kg ( except Croatia , France , Russia , Israel Netherlands low age limit 18 year ) Previous participation trial define withdrawal administration N8GP Any history FVIII inhibitor FVIII inhibitor equal 0.6 BU/mL screen HIV ( human immunodeficiency virus ) positive , define medical record CD4+ ( Tlymphocyte subtype ) count equal 200/mcL viral load 400000 copies/mL . If data available medical record within last 6 month , CD4+ measure screen visit Congenital acquire coagulation disorder haemophilia A Previous significant thromboembolic event ( e.g . myocardial infarction , cerebrovascular disease deep venous thrombosis ) define available medical record Platelet count 50,000 platelets/mcL ( laboratory value screen visit ) ALAT ( alanine aminotransferase ) 3 time upper limit normal reference range central laboratory Creatinine level equal great 1.5 time upper normal limit ( accord central laboratory reference range ) Ongoing immune modulate chemotherapeutic medication</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>